Improving Sexual Function in Postmenopausal Women


How much does ospemifene really help in the improvement of sexual function in postmenopausal women? David Portman, MD, discusses new study findings.

After menopause, some women are distressed about their inability to enjoy sex or their avoidance of intimate acts because they know it will be painful, thanks to a loss of estrogen and its effect on vulvar and vaginal tissues. Ospemifene has been approved for the treatment of dyspareunia, or painful sex, in postmenopausal women. But what kind of effect does it have on hormone levels, and how much relief does this treatment really offer?

In this video, David Portman, MD, of the Columbus Center for Women's Health Research, Columbus, Ohio, discusses what he's learned through new research on the drug and how it relates to improvement in sexual function in postmenopausal women.

This research was presented last month at the 25th Annual Meeting of The North American Menopause Society.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Navigating vasomotor symptoms in breast cancer patients | Image Credit:
Learning what women prefer in STI preventive care
Why doxycycline PEP lacks clinical data for STI prevention in women
Understanding the impact of STIs on young adults | Image Credit:
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.